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Background: The purpose of this study was to evaluate serum HE4 as a biomarker to detect recurrent disease
during follow-up of patients with endometrial adenocarcinoma (EAC).
Methods: We performed a retrospective analysis of 98 EAC patients treated at Innsbruck Medical University,
between 1999 and 2009. Twenty-six patients developed recurrent disease. Median follow-up was 5 years. Serum
HE4 and CA125 levels were analyzed using the ARCHITECT assay (Abbott, Wiesbaden, Germany) pre-operatively
(baseline), post-operative (interval) and after histological confirmation of recurrent disease or when patients returned
for clinical review with no evidence of recurrent disease (recurrence/final)). Receiver operator curves (ROC), Spearman
rank correlation coefficient, chi-squared and Mann–Whitney tests were used for statistical analysis.
Results: HE4 levels decreased after initial treatment (p = 0.001) and increased again at recurrence (p = 0.002). HE4 was
elevated (>70 pmol/L) in 21 of 26 (81%) and CA125 was elevated (>35 U/ml) in 12 of 26 (46%) patients at recurrence. In
endometrioid histology (n = 69) serum HE4 measured during follow up (Area under the curve (AUC) = 0.87, 95%CI 0.79-0.95)
was a better indicator of recurrence than CA125 (AUC= 0.67, 95%CI 0.52-0.83). A HE4 level of 70 pmol/L was associated with a
sensitivity of 84%, a specificity of 74% and a negative predictive value of 93% when assessing for recurrent endometrioid EAC.
Conclusion: This is a preliminary description of HE4 serum levels measured during routine follow up of EAC patients. Serum
HE4 measured during clinical follow-up may identify recurrent disease particularly in patients with endometrioid histology. Fur-
ther prospective validation of HE4 is warranted.
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With more than 300,000 cases occurring annually world-
wide, endometrial adenocarcinoma (EAC) is the second
most common gynecological cancer [1]. The age-
standardized incidence of EAC continues to rise through-
out the developed world [1] and this trend is expected to
continue mainly due to the increasing prevalence of obes-
ity. While the majority of patients present with early stage
disease and thus maintain a reasonable prognosis, 13-17%
of women will develop recurrent disease, generally within
3 years of primary treatment [2,3]. Three-year survival* Correspondence: ao@surgicalperformance.com
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unless otherwise stated.following recurrence is ~73% for vaginal recurrence but
less than 15% for pelvic or distant recurrence [4]. More-
over, 60% of all recurrences occur in “low risk” patients
(endometrioid subtype, low grade and stage) who are not
routinely offered adjuvant therapy, and half of these are
distant recurrences with a poor prognosis [3].
Traditionally, EAC patients are monitored in follow-
up programs for several years after primary treatment. It
is expected that recurrence can be detected early and at
a time when the tumor volume is smallest implying that
treatment of recurrence is effective [3]. Current post-
treatment surveillance guidelines differ significantly and
schedules are determined mostly by local traditions and
personal preferences. A systematic review of 16 retro-
spective studies on endometrial cancer recurrence
found little evidence to support intensive follow-up
schedules with regular diagnostic investigations, such asl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological features of 98 patients
Age























No Adjuvant treatment 5
Radiotherapy 54
Chemotherapy 19





Abreviations: IQR interquartile range, FIGO International Federation of Gynecology
and Obstetrics, LN lymph node.
Brennan et al. BMC Cancer  (2015) 15:33 Page 2 of 9vault cytology, medical imaging or serum tumour markers
[2]. Approximately 70% of patients will present with symp-
tomatic recurrence [2,3] and patients with symptomatic
recurrence have a worse overall survival than asymptom-
atic patients [3]. The Society of Gynecologic Oncologists
recommend a thorough clinical history, clinical examin-
ation and patient education of worrying symptoms as the
most effective methods of detecting recurrent EAC and
state that at present there is a lack of evidence to support
diagnostic interventions such as vault cytology or routine
imaging to monitor endometrial cancer patients for recur-
rent disease [5].
Human epididymis protein 4 (HE4), initially identified
as one of four cDNAs highly expressed in the human
epididymis [6] is a secreted protein that is overexpressed
in patients with serous and endometrioid epithelial ovar-
ian [7,8] and uterine cancers [9-11]. HE4 has proven
utility as a serum biomarker in epithelial ovarian cancer
(reviewed in [12]) and in 2009, the United States Food
and Drug Agency (FDA) approved HE4 as an aid in
monitoring recurrence or progressive disease in patients
with epithelial ovarian cancer. There is accumulating
evidence that HE4 may also prove to be a useful bio-
marker in EAC. Serum HE4 levels are increased in EAC
patients compared to healthy controls [9-11]. Increased
HE4 levels are associated with myometrial invasion
[9,13-15] and poor prognosis [9,11,13,16], however this
study focuses on HE4 and CA125 levels during clinical
follow-up after primary treatment.
The aim of this study was a) to describe the kinetics of
serum HE4 levels between baseline and the development
of recurrent disease and b) to assess the suitability of serial
serum HE4 levels as an indicator of recurrence of EAC.
Methods
Patients and specimens
Ninety-eight patients with EAC (age 40–85 years, median
65 years), all treated at the Department of Obstetrics and
Gynecology, Innsbruck Medical University, between
1999 and 2009 were included in this retrospective
study. These patients had been part of a previous study
[16], and were selected for this study based on the
availability of three consecutive blood samples. Blood
was collected at three time points – diagnosis (prior to
definitive surgery), interval and final. For the interval
time point, blood was collected when patients returned
for clinical review and did not have any clinical evi-
dence of recurrent disease. For the final time point,
blood was collected after histological confirmation of
recurrent disease or when patients returned for another
clinical review and did not have any clinical evidence of
recurrent disease.
Twenty-six patients developed recurrent disease and
72 remained disease free. Recurrent disease was definedas a histopathologically documented disease after a disease-
free interval of 3 or more months. Median follow-up time
was 5 years (range 0.6-12.6 years). Clinico-pathological
characteristics of patients are outlined in Table 1. Histo-
logical classification was performed according to WHO
criteria, and stage of disease was determined in accord-
ance with the FIGO guidelines adopted in 1998. Patients
with grade 3 tumors, serous papillary or clear cell hist-
ology, depth of invasion of more than 50% of myome-
trium, or stromal infiltration of the cervix were classified
as high-risk endometrial cancer. If all factors were negative
the patients were classified as low-risk. The extent of sur-
gery depended on disease stage, risk classification and








Median (IQR) 63 (57–71) 71 (64–77) 0.002a
FIGO Stage
1 46 (63) 12 (46) 0.064b
2 4 (5) 3 (12)
3 20 (27) 5 (19)
4 2 (3) 6 (23)
Histology
Endometrioid 50 (69) 19 (73) 0.685b
Serous Papillary/Clear cell 16 (23) 5 (19)
Carcinosarcoma 6 (8) 2 (8)
Lymph nodes
LN negative 58 (80) 18 (72) 0.500c
LN positive 13 (20) 7 (28)
Unknown 1 1
Grade
1 14 (19) 3 (12) 0.841b
2 27 (37) 12 (46)
3 30 (43) 11 (42)
Unknown 1
Risk status
Low risk 18 (25) 11 (42) 0.089c
High risk 54 (75) 15 (58)
Adjuvant treatment
No Adjuvant treatment 5 (6) 2 (8) 0.297b
Radiotherapy 44 (60) 10 (39)
Chemotherapy 10 (14) 9 (35)
Chemotherapy + radiotherapy 14 (20) 5 (19)
Median follow-up 5.36 (0.6–12.6) 2.63 (0.6–8.6)
(Years (range))
Values in parenthesis are percentages unless otherwise stated. IQR – interquartile
range, FIGO - International Federation of Gynecology and Obstetrics, LN – lymph
node. aMann–Whitney U test, bSpearman’s Correlation, cPearson Chi Squared test.
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and bilateral salpingo-oophorectomy. Para-aortic and pel-
vic lymph nodes were sampled or completely dissected.
Patients with synchronous tumours at diagnosis were ex-
cluded from the study. Patient follow-up was performed
from the date of primary treatment until last visit or death.
For the first three years patients were seen on a three
monthly basis including a gynaecological examination and
an annual CT-scan. From year 3 to 5 the patients were
invited 6 monthly and afterwards yearly. Disease stage,
histology, grade, treatment information, age, date of recur-
rence and date of last follow-up visit or death were re-
corded in all cases. The study was approved by the Ethics
Committee of Innsbruck Medical University (reference
number UN4100).
Quantitative determination of HE4 and CA125 in human
serum
Serum was stored at −80°C until analysis. Specimens were
analyzed by means of chemiluminescent microparticle im-
munoassays specific for CA125 (ARCHITECT CA125 II
assay; Abbott GmbH, Wiesbaden, Germany) or for HE4
(ARCHITECT HE4 assay; Abbott GmbH, Wiesbaden,
Germany). The dynamic range of HE4 detection goes
from 20 to 1500 pM with an automated 1:10 dilution
protocol that extends the linear range up to 15,000 pM.
The intra-assay and total imprecision (CV%) of the CMIA
HE4 assay has previously been demonstrated to range
from 2.11 to 2.93 and from 3.13 to 3.70 depending on the
concentrations of the positive controls used [17]. The
CA125 assay is linear up to 1000 U/mL and has a normal-
ity threshold at 35 U/mL.
Statistical analysis
HE4 and CA125 at each time point were compared
using Wilcoxon rank test as data were not normally dis-
tributed. All calculations were performed using IBM
SPSS Statistics version 20.0.0 (IBM Corporation, Armonk,
New York, USA). A p value < 0.05 was considered statisti-
cally significant. Receiver operator curves (ROC) were
used to compare the ability of HE4 and CA125 to identify
patients with recurrent disease. Statistical comparison of
ROC curves (StAR) was used to compare AUC values for
HE4 and CA125 as previously described [18]. No adjust-
ments have been made for multiple comparisons.
Results
Ninety-eight patients were identified with blood samples
available for the three time points. Median time from
diagnosis to interval blood sample was 33 months (range
3–138 months), and median time between interval and
final serum samples was 11 months (range 1–122 months).
Twenty-six patients developed recurrent disease and 72
patients remained disease free. Thirteen patients (50%)who developed recurrence died of their disease and me-
dian survival after recurrence was 14 months (range 0–69
months). Patients who developed recurrent disease were
older and were more likely to have stage IV disease at
presentation (Table 2). There were no significant differ-
ences in other clinic-pathological variables between pa-
tients who developed recurrent disease compared to those
that remained disease free (Table 2).
Serum HE4 and CA125 levels were significantly ele-
vated at all 3 time points in the recurrent compared to
the disease-free group (Table 3). Focusing initially on the
recurrence/final time point 21 of 26 (81%) patients had








Diagnosis 39 (20–79) 85 (40–141) 0.001a
Interval 11 (8–18) 14 (11–36) 0.033a
Final 12 (9–20) 31 (14–90) <0.001a
Median HE4 (IQR)
Diagnosis 67 (47–117) 132 (81–264) <0.001a
Interval 58 (45–89) 82 (64–119) 0.003a
Final 57 (43–92) 117 (82–197) <0.001a
HE4 at Diagnosis
< 70 pmol/L 41 (56) 3 (12) <0.001b
>70 pmol/L 32 (44) 23 (88)
Interval HE4
<70 pmol/L 49 (67) 9 (35) 0.004c
>70 pmol/L 24 (33) 17 (65)
Final HE4
<70 pmol/L 47 (64) 5 (19) <0.001c
>70 pmol/L 26 (36) 21 (81)
CA125 at Diagnosis
<35 U/ml 35 (48) 4 (15) 0.005b
>35 U/ml 38 (52) 22 (85)
Interval CA125
<35 U/ml 69 (95) 20 (77) 0.019b
>35 U/ml 4 (5) 6 (23)
Final CA125
<35 U/ml 67 (91) 14 (53) <0.001c
>35 U/ml 6 (9) 12 (47)
Values in parenthesis are percentages unless otherwise stated. IQR – interquartile
range. aMann–Whitney U test, bFisher’s exact test, cPearson Chi Squared test.
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was diagnosed. By contrast, only 36% of disease-free pa-
tients had an elevated HE4 (>70 pmol/L) during routine
post-treatment surveillance (Table 3). Twelve patients
(47%) had an elevated CA125 (>35 U/ml) at recurrence.
When combined CA125 and/or HE4 were elevated in 23
of 26 (88%) of patients with recurrent disease.
Examining the five patients with a HE4 less than 70
pmol/L at the time of recurrence (4 local, 1 distant), two
patients had an elevated serum CA125 at recurrence
and one patient had a HE4 less than 70 pmol/L at diag-
nosis. Four of these five patients had stage 1 disease (3
endometrioid and 1 papillary serous histology). The fifth
patient had stage IV uterine papillary serous carcinoma.
All of these patients had full surgical staging and re-
ceived adjuvant treatment.Serum HE4 levels decreased after initial treatment (p =
0.001) and increased again at recurrence (p = 0.002) in
patients who developed recurrence (Figure 1A). In the 26
patients who developed recurrent disease, serum HE4
levels at diagnosis (median - 132 pmol/L (Inter Quartile
Range (IQR) – 81–264 pmol/L)) did not differ significantly
from those at recurrence (median −117 pmol/L, IQR 82–
197 pmol/L) (p = 0.116). HE4 at baseline did not correlate
with HE4 at the interval time point in recurrent pa-
tients. In patients who remained disease-free and did
not develop recurrence, HE4 levels decreased after
diagnosis and remained low for both subsequent time
points (Figure 1B).
Serum HE4 levels increased at the interval time point
in 3 of 26 patients who subsequently developed recur-
rent disease, however all of these patients recurred
within 3 months of their interval sample, suggesting that
they may have had subclinical recurrence at the time of
their interval sample. These included two patients with
papillary serous carcinoma (stage III and IV) and one
patient with stage 2 endometrioid carcinoma. A higher
proportion of patients who remained disease free had a
HE4 < 70 pmol/L at the interval time point compared to
those who subsequently developed recurrent disease
(67% vs. 35%, p = 0.004) suggesting that normalization of
HE4 after initial treatment may be a prognostic factor
(Table 3).
Median serum CA125 levels fell after initial treatment
(p < 0.001) and were significantly lower at relapse com-
pared to diagnosis (p = 0.002) (Figure 1C). In disease free
patients CA125 levels decreased after diagnosis and
remained low for both subsequent time points (Figure 1D).
Serum CA125 levels fell in 24 patients after initial treat-
ment. Two patients had an increased CA125 at the inter-
val time-point one of which also had an increased interval
HE4 compared to her diagnostic HE4. Both patients had a
decrease in their CA125 at recurrence suggesting that
their CA125 may have been increased due to other rea-
sons (surgery). CA125 did not increase in a substantial
number of patients diagnosed with recurrent disease
(Figure 1B, Table 3).
For all patients area-under-the-curve (AUC) analysis
of HE4 vs. CA125 measured during follow-up revealed a
non-significant increased AUC for HE4 (AUC 0.81; 95%
CI 0.71-0.90) compared to CA125 (AUC 0.75; 95% CI
0.63-0.87; p = 0.48) (Figure 2A). The superiority of HE4
(AUC 0.81; 95% CI 0.79-0.95) over CA125 (AUC 0.67;
95% CI 0.52-0.83) (p = 0.017) to indicate recurrence dur-
ing follow-up was limited to patients with endometrioid
cell type (n = 69), (Figure 2B). A logistic regression
model combining age, HE4 and CA125 (AUC for model
0.87; 95% CI 0.80-0.94) did not improve the predictive
value of HE4 alone (AUC 0.81; 95% CI 0.71-0.90) to in-
dicate recurrence in the entire cohort (Figure 2C) or in
Figure 1 HE4 and CA125 levels in recurrent endometrial cancer. Box Plot of HE4 levels at three different time points demonstrating median
and interquartile ranges with bars demonstrating 95% confidence intervals for 26 patients who developed recurrent endometrial cancer (A) and
72 patients who remained disease free (B). Box Plot of CA125 levels at three different time points demonstrating median and interquartile ranges
with bars demonstrating 95% confidence intervals for 26 patients who developed recurrent endometrial cancer (C) and 72 patients who
remained disease free (D).
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(data not shown). The sensitivity and specificity of HE4
to indicate recurrence during follow up was assessed
using a threshold of 70 pmol/L as previously published
[13,15,19]. Serum HE4 levels of 70 pmol/L were associ-
ated with a sensitivity of 81%, a specificity of 64% and
a negative predictive value of 90% to indicate the pres-
ence of recurrence (n = 98) (Table 4). For patients with
endometrioid cell type (n = 69), a serum HE4 level of
70 pmol/L was associated with a sensitivity of 84%, aspecificity of 74% and a negative predictive value of
93% when assessing for recurrent disease. For all pa-
tients a serum CA125 level of 35 U/ml was associated
with a sensitivity of 46%, a specificity of 92% and a
negative predictive value of 83%. These figures did not
change significantly when the analysis was restricted to
endometrioid histology, where a serum CA125 level of
35 U/ml was associated with a sensitivity of 42%, a spe-
cificity of 92% and a negative predictive value of 81%
(Table 4).
Figure 2 (See legend on next page.)
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Figure 2 HE4 is a superior predictor of recurrent disease than CA125. Receiver operator curves (ROC) comparing HE4 to CA125 for identify
patients with recurrent endometrial cancer in all evaluated patients (n = 98) (A) and those with endometrioid histology (n = 69) (B). A regression
model combining age, CA125 and HE4 did not improve the sensitivity or specificity of HE4 to identify recurrent disease in the entire cohort (n = 98)
(C). AUC = area under the curve. Values in parenthesis are 95% confidence interval.
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Long-term surveillance programs for patients treated for
primary EAC focus mainly on early detection of recur-
rent disease, which occurs in 13-17% of women, mostly
within 3 years of primary treatment [2,3]. The rationale
underlying this approach being that an earlier diagnosis
of relapse correlates with a lower volume of disease,
more therapeutic options and better outcomes [3]. Con-
sistent with this hypothesis a number of studies have
demonstrated that patients with symptomatic recurrence
have significantly decreased survival compared to those
diagnosed with recurrent disease in an asymptomatic
state [3,20]. However, despite intensive surveillance,
symptomatic recurrence rates range from 41-83% [5]
and there is very little evidence to support the role of
routine vaginal cytology, imaging or CA125 in post
treatment surveillance of EAC patients [5,20]. It is there-
fore obvious that a serum biomarker to identify recur-
rent EAC during post-treatment surveillance would be
of immense clinical value.
Herein we present a serial analysis of HE4 as a bio-
marker to detect recurrent EAC. The only other analysis
of its type has only been presented in abstract format
[21]. We demonstrate that an elevated HE4 at diagnosis
generally falls after initial treatment, but increases again
in patients who develop recurrent disease, particularly in
patients with endometrioid histology. Furthermore weTable 4 Sensitivity and specificity of serum HE4 and
CA125 measured during post treatment surveillance in
detecting recurrent endometrial cancer
All patients (n = 98)





Overall accuracy 0.69 0.80
Endometrioid histology (n = 69)





Overall accuracy 0.77 0.78
PPV – positive predictive value, NPV – negative predictive value.demonstrate HE4 is elevated in 80% of patients with re-
current EAC and that a HE4 level above 70 pmol/L was
associated with a sensitivity of 81%, a specificity of 64%
and a negative predictive value of 90% when assessing
for recurrent disease. We also show that HE4 is particu-
larly relevant in patients with endometriod histology. A
70 pmol/L threshold for HE4 was chosen to identify re-
current disease as this threshold has previously been
used by us and others to identify deeply invasive tu-
mours [13,15] and was recently identified in a critical re-
view as the most sensitive and specific threshold for
primary EAC diagnostic studies [19]. The addition of
CA125 did not improve the sensitivity or specificity of
HE4 to detect recurrent EAC. The sensitivity values re-
ported herein for HE4 are significantly higher than those
reported in historical studies of CA125 in recurrent
EAC [22-24].
The strengths of this study include the fact that this is
one of the first studies of HE4 in recurrent EAC. We
used a relatively large cohort and all patients were fully
surgically staged. Serum samples were managed in stan-
dardized fashion. Weaknesses of the study include the
fact that this was a single institutional study and samples
were simply selected based on the availability of three
serum samples. In addition there were a relatively small
proportion of distant recurrences. We also only had ac-
cess to samples at three time points and thus were not
able to assess dynamic changes in HE4 and CA125 as
predictors of recurrence. Although renal failure is a
well-recognized cause of elevated HE4 in benign disease,
we were unable to control for this as baseline renal func-
tion was not available for patients in this study. Finally
we did not have data on whether patients presented with
symptomatic or asymptomatic recurrence, which would
be helpful when determining the clinical relevance of
HE4 in detecting recurrent EAC.
These data suggest that HE4 may be an effective bio-
marker in post treatment surveillance of EAC. The dy-
namics of HE4 in EAC are an elevation in a significant
proportion of patients at diagnosis, a significant decrease
after initial surgery followed by another significant rise if
recurrent disease develops. In contrast we and others
have previously demonstrated that patients with a low
pre-operative HE4 generally have early stage disease with
a low risk of developing recurrence and may not require
intensive post operative surveillance [13,16]. Although
these findings are preliminary and require validation in
independent prospective cohorts, they suggest that HE4
Brennan et al. BMC Cancer  (2015) 15:33 Page 8 of 9may be used to triage and monitor EAC patients at high
risk of recurrence, particularly in patients with low-
grade endometrioid histology who would generally be
considered at low risk of developing recurrent disease.
Further studies are required to validate the 70 pmol/L
threshold and also to assess the correct time intervals
for HE4 analysis in the follow-up schedule. In addition
further longitudinal studies are required to investigate
the importance of dynamic changes in HE4 over time in
a similar fashion to how PSA is used in prostate cancer
and CA125 in ovarian cancer screening studies.
Conclusion
In summary, these data are a preliminary description of
HE4 in recurrent EAC and suggest that it may be a sen-
sitive and specific predictor of recurrent disease particu-
larly in patients with endometrioid histology. HE4 is
elevated in 81% of patients with recurrent endometrioid
EAC and is significantly superior than CA125 as a pre-
dictor of recurrent disease. The sensitivity and NPV values
presented are similar to those published for CA125 in post
treatment surveillance of epithelial ovarian cancer [5,25]
suggesting that further prospective analysis of HE4 in post
treatment surveillance of EAC is warranted. Given the fact
that following CA125 in post treatment surveillance of
ovarian cancer does not impact on survival [26], future
studies of HE4 in endometrial cancer follow-up should
focus on the impact of HE4 on clinical decision-making
and whether it has any impact on survival.
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